A diimmistration of a variety of noonfibrinolytic, noanenizymImatic substances imdluces fibrinmolvsis in moan. The most potent materials of this type known at present are purified protein-fre( pyrogenms. Their action after intravenous injection on the huiman fibrinolytic system, on some of its componemIts, and on the clotting system of 67 individuals has been studied. The possible therapeutic immplications are discussed of th-ninarked fibrinolysis.
THE obvious therapeutic value of activation of fibrin-dissolving potelntialities of the circulatinog human blood in throniboembolic disorders, has stimulated many efforts to achieve this goal. These attempts may be classified under 2 geiieral headiugs: inljection of proteolytic enzymes, aiid the activation of plasminogen in the body itself. The most important dIrugs known to produce fibrinolysis in human beings and some of their characteristics are summarized in table 1 .
The induction of fibrinolvsis in the human l)ody with niomieizymnatic material can be produced (table 1) in nmany ways. In the miajority of cases, however, the fibrinolytic reactions are either weak or too irregular to be of therapeutic value.
The observation of Eichenberger,'3 that Westphal '514 highly purified proteini-free pyrogen produces fibrinol-sis in man after iiitraveiious injection, was therefore of special interest. We have confirmed these preliminary findings and have extended these observatioiis considerably with more comprehensive studies. The protein-free pyrogens described below, as far as we have been able to determine, are the niost potent noneinzy-inatic fibrinioly-sis-iniducini(r agents kniown1 at present. 
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In this paper the I)pyrogreniie materials used and their action ini mati are described with special emphasis oni fibrinolysis. A short summary of some of our experiments has previoulsly-been given.1-
MATERIAL AND METHODS
Pqroye!s. Two pyrogens were used. 1. Preparation 1064 is derived fromn Sa(lmloniellai abortus equi and has a molecular weight of about 1 to 2,000,000. It consists of 30 to 40 per cent phospholipids, 6 to 10 per cent esters of phosphoric acid, and 5.5 to 60 per cent different sugars and is free froni proteins and amino acids. 2 Fib-iinolyNis. (. ) A continuous recording (coagulograimi) of fibrin formation and dissolution of recalcified citrated plasma'6 was made. One part of 3.8 per cent sodium citrate to 4 parts of blood was used, spun for 5 minutes at 1,500 g and recalcified with one tenth volume of 0.5 molar cal- ulin technic than by undiluted plasma lysis. Figure 4 illustrates again the relation of euglobulin to undiluted plasma lysis time.
Ilere the results of all tests done during pyrogen treatment of patient no. 14 are shown graphically. This patient had a marked fibrinolysis without any significant temperature elevation. The 5-hour specimen showed a reduced eulglobulini lysis time and there was mio lysis in the plasma specimen at all; lysis was detectable only by the euglobulin techiiic. Figure 4 shows also another phenomenon which we call the rebound effect, and which is discussed in the following paragraph.
Rebouinid Effect anid T'oleranice. The euglobulin lysis time of the last 2 samples of the serial deterininations of patient no. 14 represented in figure 4 figure 5 . The arrows pointing downward in the lower row show the antifibrinolysin activity as expressed in minutes of lysis time of the system, diluted albumin-fraetion bovine-fibrinolysin bovine-fibrinogen-thrombin. There was no spontaneous fibrinolysis in the control without fibrinolysin, when the albumin fraction was prepared from the most active fibrinolytic samples. Figure 5 shows that the antifibrinolysin activity increases considerably 60 minutes after intravenous injection of the pyrogen. The antifibrinolysin activity is then reduced, but does not disappear entirely even at the peak of fibrinolytic activity. Subsequently it returns with some fluctuations to values exceeding the preinjection levels. Of interest is the " rebound effect " producing a euglobulin lysis time in samples 6, 7, and 8 considerably longer than those of the preinjection sample. The rebound effect of sample 6 coincides with a reduced antifibrinolysin activity. This observation, made repeatedly, led us to the conclusion that antifibrinolysin activity is not related to the rebound effect. The general pattern of antifibrinolysin activity in patients with pyrogeninduced fibrinolysis is basically that shown in figure 5 . There is commonly a rise in activity in the first hour after injection, then a reduction of activity at peak fibrinolysis and for a short time thereafter. Then Blood Pressure and Blood. The blood showed the known response to pyrogens: lymphopenia, eosinopenia, and leukopenia followed by leukoeytosis. We have seen no critical fall of blood pressure; however, hypertensive patients were not treated. In some instances there was a drop of 10 to 15 mm. Hg for a few minutes in the first 2 hours after injection. One patient (no. 56) showed marked transitory hypotension.
Miscellaneous. Paracoagulation. In several instances it was observed that a narrowing of the coagulogram due to fibrinolysis was interrupted by a new widening followed by a narrowing as fibrinolysis proceeded to completion ( fig. 1, 135-minute sample) . In some cases, even after a complete lysis, a new minor clotting took place followed by a new lysis. This phenomenon of a new partial coagulation, after the sample had lysed completely, was first observed by Derechin23 and designated as paracoagulation. At present we explain this as an incomplete transformation of fibrinogen into fibrin in the sample and by a subsequent release of the thrombin adsorbed on fibrin during fibrinolysis. This Storage. The activity of the frozen samples decreased only gradually when frozen at -15 C. Half of the activity was found in 1 sample after 10 months' storage. Animal Studies. It was not possible to induce fibinolysis with pyrogens used in this study in rabbits and dogs.
DIscussIoN
The injection of highly purified pyrogens enables us to induce a marked fibrinolysis in human beings. Pyrogen injection, which is only one of many stimuli that can bring about fibrinolysis in man, is the most potent of nonenzymatic or nonproteolytic nature known at present. The stimulating material may be of endogenous or of exogenous origin. In the case of endogenous origin, the pathologic release of an activator for plasminogen (from prostate, uterus, or lung) is the probable method of activation. The mechanism of action of such exogenous-stimulating materials as epinephrine, acetylcholin, anesthetics,25 butazolidine, paraaminobenzoid acid, pituitary extracts, and other agents has not been clarified. None of these materials has any fibrinolytic or plasminogen-activating properties in vitro. According to our observations the activity of antiplasmin plays no prominent part in the appearance of fibrinolytic activity after administration of these substances, provided the stimulus is strong In our series fibrinolysis was studied in the dissolution of clots that were formed in a fibrinolytic milieu, thus ensuring a thorough distribution of the enzyme within the clot. This could rarely happen in the human origin. In vivo the enzyme must work on a clot already formed. It can attack only from the exterior and not from within. These conditions are partially duplicated by the use of fibrin plates. To study the therapeutic possibilities of the fibrinolytic system further, standard clots in vitro formed in the absence of fibrinolytic enzymes must be used. These studies are currently under way in our laboratories.
Our preliminary clinical observations combined with the findings of other students of the problem in human beings and in animals indicate that the clot already formed in the circulatory system can very well become smaller or disappear completely, if the circulating blood possesses marked fibrinolytic activity. It seems also to be true that the fibrinolytic distintegration of the preformed clot continues for some time after disappearance of fibrinolysis in the circulating blood. Extensive studies will be required to substantiate these preliminary observations. The great affinity of the fibrinolytic enzyme for fibrin is well known. One of the early fibrinolytic preparations was obtained from autolyzed fibrin.31
The data presented in this paper indicate that very marked fibrinolysis can easily and regularly be induced in human beings by injecting purified pyrogens. In none of our cases with marked induced lysis did bleeding occur. This was particularly remarkable for one case with low fibrinogen and prothrombin levels due to advanced liver cirrhosis (patient no. 5 ) and for all the postpartal patients who showed no increase in the blood content of their lochiae. In retrospect these observations are not too astonishing for the following reason. The fibrinolytic reaction in our series was induced by 2 pyrogens of different origin. Furthermore, Italian investigators have used pyrogenic typhoid vaccine for fibrinolytic treatment of thromboembolic disorders. We are entitled to assume that other pyrogens will have similar effects with possible side reactions. One wonders how many patients might have had a more or less marked fibrinolysis since the introduction of fever therapy by the injection of pyrogenic material.
At present we have limited our studie; on pyrogen-induced fibrinolysis and its therapeutic applications to those conditions in which fever therapy is not contraindicated. This limitation excludes many situations in which attempts to dissolve a clot would be highly desirable as in coronary occlusion. On the other hand, we are in a position for the first time to induce a very marked fibrinolysis, with a high rate of success without resorting to enzymatic fibrinolytic material in human beings. We are thus able to study the phenomenon of fibrinolysis in human subjects more extensively and can acquire information useful in achieving the ultimate goal of safely bringing about the dissolution of intravascular clots.
SUMMARY
The mechanism of pyrogen-induced fibrinolysis has been studied in 67 individuals. 
